Biomarkers of Immune Function as Predictors of Head and Neck Squamous Cell Carcinoma (HNSCC) in Response to Therapy
This is a study of the immune response in patients with oropharyngeal cancer who undergo
treatment with radiation, chemoradiation, or robotic surgery. Many oropharyngeal cancers
are caused by infection with the human Papillomavirus (HPV), and patients with HPV-mediated
tumors have much better prognosis and treatment response compared to patients with
HPV-negative tumors. The investigators will test the hypothesis that radiation-based
therapy of oropharyngeal cancer is associated with activation of the endogenous HPV-specific
immune response. In this study the investigators will collect blood at several time points
before, during, and after treatment to monitor the immune response in patients with tumors
positive and negative for HPV versus normal healthy volunteers.
Observational
Observational Model: Case Control, Time Perspective: Prospective
HPV-specific T-cell response
at time of enrollment into study (baseline)
No
Andrew Sikora, MD, PhD
Principal Investigator
Mount Sinai School of Medicine
United States: Institutional Review Board
GCO # 10-1219
NCT01358097
October 2010
December 2012
Name | Location |
---|---|
The Mount Sinai Medical Center, Otolaryngology - Head and Neck Surgery | New York, New York 10029 |